Strattera (correction)
Executive Summary
Lilly's attention deficit/hyperactivity disorder medication Strattera has been used in 3.4 mil. patients worldwide, the company says. "The Pink Sheet" (1Oct. 2, 2005, p. 8) incorrectly reported the figure as 2 mil. based on an FDA press release. Additionally, labeling for Shire's Adderall XR was inaccurately reported in the story. The amphetamine therapy carries a "black box" warning advising of drug dependence. A similar boxed warning is included under the Warnings section of Johnson & Johnson's Concerta...